These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35727156)

  • 1. Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non-Small Cell Lung Cancer.
    Chen WM; Chen M; Hsu JG; Lee TS; Shia BC; Wu SY
    Radiology; 2022 Oct; 305(1):219-227. PubMed ID: 35727156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of preoperative [
    Lin JT; Li XM; Zhong WZ; Hou QY; Liu CL; Yu XY; Ye KY; Cheng YL; Du JY; Sun YQ; Zhang FG; Yan HH; Liao RQ; Dong S; Jiang BY; Liu SY; Wu YL; Yang XN
    Ann Nucl Med; 2024 Mar; 38(3):188-198. PubMed ID: 38145431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistency and prognostic value of preoperative staging and postoperative pathological staging using
    Kajiyama A; Ito K; Watanabe H; Mizumura S; Watanabe SI; Yatabe Y; Gomi T; Kusumoto M
    Ann Nucl Med; 2022 Dec; 36(12):1059-1072. PubMed ID: 36264439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
    Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
    Li C; Tian Y; Shen Y; Wen B; He Y
    AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
    Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
    Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
    Park HL; Yoo IR; Boo SH; Park SY; Park JK; Sung SW; Moon SW
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1021-1026. PubMed ID: 30756189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic tumor burden quantified on [
    Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer.
    Geredeli C; Artac M; Kocak I; Koral L; Sakin A; Altinok T; Kaya B; Karaagac M
    J Cancer Res Ther; 2020; 16(4):816-821. PubMed ID: 32930124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-IIIB Squamous Cell Carcinoma of the Lungs.
    Lin WC; Chen WM; Chen M; Shia BC; Wu SY
    Clin Nucl Med; 2022 Aug; 47(8):677-683. PubMed ID: 35695702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
    Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
    Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
    Guberina M; Eberhardt W; Stuschke M; Gauler T; Aigner C; Schuler M; Stamatis G; Theegarten D; Jentzen W; Herrmann K; Pöttgen C
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1439-1447. PubMed ID: 30710323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].
    Ren H; Xu W; You J; Song X; Huang H; Zhao N; Ren X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):192-9. PubMed ID: 27118646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.